Skip to content

OS Therapies OSTX Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

CTO
Citius Oncology, Inc.CTOR
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
Arcus Biosciences logo
Arcus BiosciencesRCUS
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's common stock, par value (in dollars per share)?
OS Therapies (OSTX) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
How has OS Therapies's common stock, par value (in dollars per share) changed year-over-year?
OS Therapies's common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for OS Therapies's common stock, par value (in dollars per share)?
Over 2 years (2023 to 2025), OS Therapies's common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.